Noticias de OGEN_US

Noticias del mercado

Últimas noticias sobre OGEN_US — 71 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: OGEN_US ✕ 71 resultados
05/05/2026 OGEN_US — Investing.com ES ← EN
Oragenics añade un segundo centro a un ensayo de fármacos para la conmoción cerebral en Australia Por Investing.com

Oragenics adds second site to concussion drug trial in Australia By Investing.com

05/05/2026 OGEN_US — Investing.com ES ← EN
Oragenics añade un segundo centro a un ensayo de fármacos para la conmoción cerebral en Australia Por Investing.com

Oragenics adds second site to concussion drug trial in Australia By Investing.com

05/05/2026 OGEN_US — GlobeNewswire ES ← EN
Oragenics activa el segundo sitio en el ensayo clínico de fase IIa de ONP-002 para conmociones cerebrales y lesiones cerebrales traumáticas leves.

SARASOTA, Florida, 05 de mayo de 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), una empresa de biotecnología en etapa clínica que desarrolla productos dirigidos al cerebro...

05/05/2026 OGEN_US — Investing.com
Oragenics adds second site to concussion drug trial in Australia
05/05/2026 OGEN_US — MEXC
Oragenics Expands Phase IIa Trial for Concussion Treatment to Second Site
05/05/2026 OGEN_US — Sahm
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
05/05/2026 OGEN_US — Yahoo Finance
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
26/04/2026 OGEN_US — MSN
Oragenics shares plunge following announcement of $20 million preferred stock sale
25/04/2026 OGEN_US — MSN ES ← EN
Las acciones de Oragenics se desploman tras el anuncio de la venta de acciones preferentes por 20 millones de dólares

Oragenics shares plunge following announcement of $20 million preferred stock sale

24/04/2026 OGEN_US — MSN ES ← EN
Las acciones de Oragenics se desploman tras el anuncio de la venta de acciones preferentes por 20 millones de dólares

Oragenics shares plunge following announcement of $20 million preferred stock sale

24/04/2026 OGEN_US — ChartMill
OGEN News | ORAGENICS INC (NYSEARCA:OGEN)
21/04/2026 OGEN_US — MSN
Oragenics shares plunge following announcement of $20 million preferred stock sale
20/04/2026 OGEN_US — GuruFocus
Oragenics (OGEN) Advances in Phase IIa Trial for Concussion Trea
20/04/2026 OGEN_US — The Manila Times
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
20/04/2026 OGEN_US — GlobeNewswire
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
20/04/2026 OGEN_US — citybuzz -
Oragenics Reports Early Progress in Phase IIa Trial of Intranasal Concussion Therapy
20/04/2026 OGEN_US — GlobeNewswire
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
20/04/2026 OGEN_US — Stock Titan
Concussion has no approved drug; Oragenics doses 2 in trial
20/04/2026 OGEN_US — Yahoo Finance
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
15/04/2026 OGEN_US — ChartMill
OGEN Ownership | ORAGENICS INC (NYSEARCA:OGEN)

Página 2 de 4

keyboard_arrow_up